Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27933541 | 0.80 | FABP4 (0.51) | MEN1KMT2AF2RHPGDALDH1A1 | |
| SCHEMBL9579742 | 0.78 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL28677921 | 0.76 | KDM4E (0.54) | NPC1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL4806049 | 0.76 | CES2 (0.60) | MEN1KMT2AHPGDALDH1A1POLB | |
| SCHEMBL30725459 | 0.76 | CES2 (0.60) | MEN1KMT2AHPGDALDH1A1POLB | |
| SCHEMBL26978962 | 0.75 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12204783 | 0.74 | ALDH1A1 (0.39) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19332963 | 0.74 | CES2 (0.58) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11643111 | 0.74 | HPGD (0.46) | SMN1; SMN2KMT2AELANEHPGDALDH1A1 | |
| SCHEMBL17244263 | 0.74 | MAPT (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263933-A | Alpha-carboline derivative and synthesis method thereof | 湘潭大学 | 2023-12-22 | — | — | CN | claimed |
| CN-117263933-A | Alpha-carboline derivative and synthesis method thereof | 湘潭大学 | 2023-12-22 | — | — | CN | disclosed |
| US-20180111889-A1 | METHODS OF MAKING MULTICYCLIC COMPOUNDS USING MULTICOMPONENT/TANDEM REACTION SEQUENCES | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016153906-A1 | METHODS OF MAKING MULTICYCLIC COMPOUNDS USING MULTICOMPONENT/TANDEM REACTION SEQUENCES | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111889-A1 | METHODS OF MAKING MULTICYCLIC COMPOUNDS USING MULTICOMPONENT/TANDEM REACTION SEQUENCES | TYMS, RTCB, POLRMT | NPC1 3101/4885RAB9A 3657/4885SMN1; SMN2 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.